Are you striving to provide personalised treatment recommendations to every patient in your routine cancer care in a timely and cost-effective manner? 


We are expanding our Clinical Decision Support (CDS) platform in Europe into Oncology and are looking for participants in our Early Access Program.


Despite advances in biomarker-based drug approvals and availability, precision oncology medicine remains largely underutilised in routine cancer care. Our scalable, future-prove and fully automated end-to-end solution is designed to rapidly provide personalised therapy recommendations in routine clinical practice.

product graphic

Key Features and Benefits  

  • Fully automated, scalable and future-proof diagnostic NGS data analysis and reporting platform to improve turnaround times and operational efficiency
  • Automated, evidence-based driver variant classification for rapid and unbiased variant interpretation 
  • Integrated clinical knowledgebase for rapid therapeutic matching & personalised treatment recommendations
  • Easy-to-interpret report focused on actionable insights to accelerate patient treatment 
  • CE/IVD approved software for highest confidence in diagnostic outcomes. 

If you are using TSO500 in your routine oncology diagnostics workflow and are interested in participating in our European Early Access Program, please complete the form below.